Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

A Phase 3 Study of TVP-1012 (1 mg) in Early Parkinson's Disease Patients

17. februar 2022 oppdatert av: Takeda

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of TVP-1012 at 1 mg in Early Parkinson's Disease Patients Not Treated With Levodopa

The purpose of this study is to evaluate the efficacy and safety of TVP-1012 (1 mg/day) administered to Japanese patients with early Parkinson's disease.

Studieoversikt

Status

Fullført

Detaljert beskrivelse

This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 study to evaluate the efficacy and safety of TVP-1012 in Japanese participants with early Parkinson's disease.

The study period consisted of a 28-week trial period. The participants who fulfill the inclusion criteria and not meeting any of the exclusion criteria were enrolled, and randomized in a 1:1 ratio to either the 1 mg of TVP-1012 or the placebo group. In each treatment group, participants received either 1 mg of TVP-1012 or placebo once daily in a double-blinded manner.

Studietype

Intervensjonell

Registrering (Faktiske)

244

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Akita, Japan
      • Aomori, Japan
      • Fukuoka, Japan
      • Fukushima, Japan
      • Hiroshima, Japan
      • Kochi, Japan
      • Kyoto, Japan
      • Niigata, Japan
      • Okayama, Japan
      • Osaka, Japan
      • Tokushima, Japan
      • Toyama, Japan
      • Wakayama, Japan
      • Yamagata, Japan
    • Aichi
      • Nagoya, Aichi, Japan
    • Ehime
      • Matsuyama, Ehime, Japan
      • Touon, Ehime, Japan
    • Fukuoka
      • Kitakyushu, Fukuoka, Japan
      • Onoshiro, Fukuoka, Japan
    • Hokkaido
      • Asahikawa, Hokkaido, Japan
      • Iwamizawa, Hokkaido, Japan
    • Hyogo
      • Akashi, Hyogo, Japan
      • Kobe, Hyogo, Japan
    • Ibaragi
      • Tsuchiura, Ibaragi, Japan
      • Tsukuba, Ibaragi, Japan
    • Iwate
      • Morioka, Iwate, Japan
    • Kagawa
      • Takamatsu, Kagawa, Japan
    • Kanagawa
      • Fujisawa, Kanagawa, Japan
      • Sagamihara, Kanagawa, Japan
      • Yokohama, Kanagawa, Japan
    • Kumamoto
      • Goushi, Kumamoto, Japan
    • Miyagi
      • Sendai, Miyagi, Japan
    • Nagano
      • Matsumoto, Nagano, Japan
    • Nagasaki
      • Higashisonogi-gun, Nagasaki, Japan
      • Nishisonogi-gun, Nagasaki, Japan
    • Nara
      • Tenri, Nara, Japan
    • Niigata
      • Jouetsu, Niigata, Japan
    • Osaka
      • Higashiosaka, Osaka, Japan
      • Suita, Osaka, Japan
      • Takatsuki, Osaka, Japan
      • Toyonaka, Osaka, Japan
    • Saitama
      • Irima-gun, Saitama, Japan
    • Shizuoka
      • Fuji, Shizuoka, Japan
      • Hamamatsu, Shizuoka, Japan
      • Izunokuni, Shizuoka, Japan
    • Tochigi
      • Shimono, Tochigi, Japan
    • Tokushima
      • Yoshinogawa, Tokushima, Japan
    • Tokyo
      • Bunkyo-ku, Tokyo, Japan
      • Fuchu, Tokyo, Japan
      • Kodaira, Tokyo, Japan
      • Meguro-ku, Tokyo, Japan
      • Nerima-ku, Tokyo, Japan
      • Ota-ku, Tokyo, Japan
      • Setagaya-ku, Tokyo, Japan
      • Shibuya-ku, Tokyo, Japan

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

30 år til 80 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

Run-in period

  • In the opinion of the investigator or sub-investigator, the participant is capable of understanding and complying with protocol requirements.
  • The participant signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.
  • The participant has a diagnosis of Parkinson's disease with at least two of the following signs: resting tremor, akinesia/bradykinesia, and muscle rigidity.
  • The participant has a Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II + Part III total score of >=14 at the start of the run-in period.
  • The participant has Modified Hoehn & Yahr stage 1 to 3 at the start of the run-in period.
  • The participant has the Parkinson's disease diagnosed within 5 years prior to the start of the run-in period.
  • The participant is an outpatient of either sex aged >= 30 and < 80 years.
  • A female participant of childbearing potential who is sexually active with a nonsterilized male partner agrees to use routinely adequate contraception from signing of informed consent to 1 month after the last dose of the investigational drug.

Treatment period

- The participant has a MDS-UPDRS Part II + Part III total score of >= 14 at baseline.

Exclusion Criteria:

Run-in period

  • The participant has received any investigational medication within 90 days prior to the start of the run-in period.
  • The participant has received TVP-1012 in the past.
  • The participant is study site employee, an immediate family member, or in a dependent relationship with a study site employee who is involved in the conduct of this study (e.g., spouse, parent, child, sibling) or may consent under duress.
  • Participant has donated 400 mL or more of his or her blood volume within 90 days prior to the start of the run-in period.
  • The participant has unstable systemic disease.
  • The participant has Mini-Mental State Examination (MMSE) score of <= 24 at the start of the run-in period.
  • The participant has known or a history of schizophrenia, major or severe depression, or any other clinically significant psychiatric disease.
  • The participant has a history of hypersensitivity or allergies to TVP-1012 (including any associated excipients) or selegiline.
  • The participant has a history of clinically significant hypertension or other reactions associated with ingestion of tyramine-rich food (e.g., cheese, lever, herring, yeast, horsebean, banana, beer or wine).
  • The participant has a history or concurrent of drug abuse or alcohol dependence.
  • The participant has received neurosurgical intervention for Parkinson's disease (e.g., pallidotomy, thalamotomy, deep brain stimulation).
  • The participant has received transcranial magnetic stimulation within 6 months prior to the start of the run-in period
  • The participant has received amantadine or anticholinergic medication for >= 180 days.
  • The participant has received selegiline, a levodopa-containing product or dopamine agonist for >= 90 days.
  • The participant has received selegiline, pethidine, tramadol, reserpine or methyldopa within 90 days prior to the start of the run-in period.
  • The participant has received a levodopa-containing product, dopamine agonist, amantadine or anticholinergic drug within 30 days prior to the start of the run-in period.
  • The participant has received any psychoneurotic agent or antiemetic medication of dopamine antagonist within 14 days prior to the start of the run-in period. However, the participant has been receiving quetiapine or domperidone with a stable dose regimen for >= 14 days prior to the start of the run-in period may be included in the study.
  • The participant has previously received a catechol-O-methyltransferase (COMT) inhibitor, droxidopa, zonisamide or istradefylline.
  • The participant is required to take any of the prohibited concomitant medications or treatments.
  • If female, the participant is pregnant or lactating or intending to become pregnant during this study, or within 1 month after the last dose of the investigational drug; or intending to donate ova during such time period.
  • The participant has clinically significant neurologic, cardiovascular, pulmonary, hepatic (including mild cirrhosis), renal, metabolic, gastrointestinal, urological, endocrine, or hematological disease.
  • The participant has clinically significant or unstable brain or cardiovascular disease, such as:

    • clinically significant arrhythmia or cardiac valvulopathy,
    • cardiac arrest of NYHA Class II or higher,
    • concurrent or a history of ischemic cardiac disease within 6 months prior to the start of the run-in period,
    • concurrent or a history of clinically significant cerebrovascular disease within 6 months prior to the start of the run-in period,
    • sever hypertension (systolic blood pressure of 180 mmHg or higher, or diastolic blood pressure of 110 mmHg or higher),
    • clinically significant orthostatic hypotension (including those with systolic pressure decrease of 30 mmHg or more following postural change from supine/sitting position to standing position),
    • a history of syncope due to hypotension within 2 years prior to the start of the run-in period.
  • The participant is required surgery or hospitalization for surgery during the study period
  • Participant has a history of cancer within 5 years prior to the start of the run-in period, except cervix carcinoma in situ which has completely cured.
  • The participant has acquired immunodeficiency syndrome (AIDS) [including human immunodeficiency virus (HIV) carrier], or hepatitis [including viral hepatitis carrier such as hepatitis B surface (HBs) antigen or hepatitis C antibody (HCV) positive]. However, the participant who has a negative result for HCV antigen or HCV-RNA can be included in the study.
  • The participant who, in the opinion of the investigator or sub-investigator, is unsuitable for any other reason.

Treatment period

  • The participant whose diagonosis of Parkinson's disease is ruled out by dopamine transporter scintigraphy performed during the run-in period if conducted.
  • The participant has laboratory data meeting any of the following at the start of the run-in period:

    • Creatinine >= 2 x upper limit of normal (ULN)
    • Total bilirubin >= 2 x ULN
    • ALT or AST >= 1.5 x ULN
    • ALP >= 3 x ULN
  • The participant has received any of the prohibited concomitant medications or treatments during the run-in period.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: TVP-1012 1 mg
For 2 weeks during the run-in period, one tablet of placebo orally, once daily before or after breakfast, followed by 26 weeks during the treatment period, one tablet of TVP-1012 1 mg orally, once daily before or after breakfast.
TVP-1012 1mg Tablets
Placebo komparator: Placebo
For 2 weeks during the run-in period, one tablet of placebo orally, once daily before or after breakfast, followed by 26 weeks during the treatment period, one tablet of placebo orally, once daily before or after breakfast.
Placebotabletter

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change From Baseline in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II + Part III Total Score
Tidsramme: From Baseline to Week 26 (LOCF)
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) retains the four-scale structure with a reorganization of the various subscale; (Part I; 13 items) non-motor experiences of daily living, (Part II; 13) motor experiences of daily living, (Part III; 34) motor examination, and (Part IV; 6) motor complications. Each items had 0-4 ratings, where 0 (normal) to 4 (severe) and score for each was summed to calculate the total scores. The scale range for Part II+III Total Score was 0-188, with higher scores reflecting greater severity.
From Baseline to Week 26 (LOCF)

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Antall deltakere som opplever minst én behandling Emergent Adverse Events (TEAEs) og Serious Adverse Events (SAEs)
Tidsramme: Frem til uke 26
Frem til uke 26
Antall deltakere med markert unormale vitale tegnverdier
Tidsramme: Frem til uke 26
Frem til uke 26
Antall deltakere med TEAE relatert til kliniske laboratorietester
Tidsramme: Frem til uke 26
Frem til uke 26
Change From Baseline in MDS-UPDRS Part I Total Score
Tidsramme: Baseline and Week 26 (LOCF)
For MDS-UPDRS Part I (non-motor experiences of daily living) scores, the scale range for Part I Total Score was 0-52, with higher scores reflecting greater severity.
Baseline and Week 26 (LOCF)
Change From Baseline in MDS-UPDRS Part II Total Score
Tidsramme: Baseline and Week 26 (LOCF)
For MDS-UPDRS Part II (motor experiences of daily living) scores, the scale range for Part II Total Score was 0-52, with higher scores reflecting greater severity.
Baseline and Week 26 (LOCF)
Change From Baseline in MDS-UPDRS Part III Total Score
Tidsramme: Baseline and Week 26 (LOCF)
For MDS-UPDRS Part III (motor examination) scores, the scale range for Part III Total Score was 0-132, with higher scores reflecting greater severity.
Baseline and Week 26 (LOCF)
Number of Participants With TEAE Related to Body Weight
Tidsramme: Up to Week 26
Up to Week 26
Number of Participants With TEAE Related to Electrocardiograms (ECG)
Tidsramme: Up to Week 26
Up to Week 26

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

7. februar 2015

Primær fullføring (Faktiske)

15. september 2016

Studiet fullført (Faktiske)

15. september 2016

Datoer for studieregistrering

Først innsendt

9. januar 2015

Først innsendt som oppfylte QC-kriteriene

9. januar 2015

Først lagt ut (Anslag)

14. januar 2015

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

2. mars 2022

Siste oppdatering sendt inn som oppfylte QC-kriteriene

17. februar 2022

Sist bekreftet

1. februar 2022

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • TVP-1012/CCT-001
  • U1111-1165-1302 (Registeridentifikator: WHO)
  • JapicCTI-152760 (Registeridentifikator: JapicCTI)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Tilgangskriterier for IPD-deling

IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • SEVJE
  • ICF
  • CSR

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere